The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Open accessAbstract
Increased translocation of intestinal bacteria is a hallmark of chronic liver disease and contributes to hepatic inflammation and fibrosis. Here we tested the hypothesis that the intestinal microbiota and Toll-like receptors (TLRs) promote hepatocellular carcinoma (HCC), a long-term consequence of chronic liver injury, inflammation, and fibrosis. Hepatocarcinogenesis in chronically injured livers depended on the intestinal microbiota and TLR4 activation in non-bone-marrow-derived resident liver cells. TLR4 and the intestinal microbiota were not required for HCC initiation but for HCC promotion, mediating increased proliferation, expression of the hepatomitogen epiregulin, and prevention of apoptosis. Gut sterilization restricted to late stages of hepatocarcinogenesis reduced HCC, suggesting that the intestinal microbiota and TLR4 represent therapeutic targets for HCC prevention in advanced liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, HSC mediators besides RSPO3, such as HGF, but possibly also neurotrophin-319 or epiregulin60 may be involved in additional aspects of HSC–hepatocyte cross-talk and—together with ECs29,59—collaboratively control hepatocyte health and functions.”
From Hepatic stellate cells control liver zonation, size and functions via R-spondin 3 (2025) · cites this paper as [60]
In the citing paper
“These pro-inflammatory mediators not only promote the development of CLD but also set the stage for the development of HCC13–15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“However, a failing gut barrier and alterations of the gut microbiota in chronic liver disease (CLD) contribute to chronic inflammation and the progression of liver diseases12, and thereby increase risk for the development of hepatocellular carcinoma (HCC) as the final stage of the disease process 13–15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Nonetheless, the bacterial microbiota has an important role in promoting HCC in the setting of liver fibrosis, as demonstrated by reduced HCC formation in TLR4-deficient, germ-free and antibiotic-treated mice in a diethylnitrosamine (DEN) plus CCl4 model of HCC13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“It has become apparent that the endogenous commensal microbiota provides hepatoprotective signals and that complete absence of the gut microbiota results in increased liver injury — probably owing to an absence of TLR4-mediated activation of anti-apoptotic NF-κB signalling — and a subsequent increase in liver fibrosis, as demonstrated in several models13,75,76.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Consistent with previous studies71–73, treatment with nonabsorbable antibiotics resulted in a strong reduction of fibrosis despite increased liver injury13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Experiments in bone-marrow-chimeric mice demonstrated that TLR4 expressed on liver-resident cells (which include hepatocytes, HSCs and Kupffer cells) is responsible for promotion of fibrogenesis and hepatocarcinogenesis13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Accordingly, epiregulin-deficient mice displayed reduced hepatocarcinogenesis when treated with DEN+CCl413.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Conversely, inhibition of TLR4 signalling suppresses liver inflammation, fibrosis and HCC formation in mice and rats13,14,73.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Accordingly, chronic infusion of low-dose LPS via osmotic pumps promotes HCC development in mice13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“As such, HCC development induced by the combination of DEN and CCl4 was attenuated in gut-sterilized and germ-free mice compared with their specific pathogen-free counterparts13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Accordingly, expression of the apoptosis marker cleaved caspase 3 in TLR4-deficient and gut-sterilized mice is inversely correlated with the formation of tumours13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“In HSCs, TLR4 activation leads to an NF-κB-mediated upregulation of the hepatomitogen epiregulin13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Continuous gut sterilization by a cocktail of oral antibiotics, consisting of ampicillin, neomycin, metronidazole and vancomycin, effectively reduced the number and size of HCC induced by DEN+CCl4 or DMBA+HFD in mice13,15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Of note, rifaximin reduces HCC development in the DEN–CCl4 model of HCC, albeit less efficiently than the quadruple antibiotics cocktail described above13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Of note, administration of antibiotics at late stages of carcinogenesis, when microscopic tumours already existed, was more efficient at reducing HCC in mice than administration at earlier stages13.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“supported by a large number of studies preclinical studies showing a drastic (≈80%) reduction of HCC development in murine models13–15.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
In the citing paper
“Several studies have shown a key role for the TLR4 pathway as a mediator of the disease-promoting effects of the gut–liver axis in CLD and hepatocarcinogenesis13,14,73.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
Wang, C.-Y., Mayo, M., Korneluk, R., Goeddel, D., & Baldwin, A. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,950
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,587
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben‐Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,423
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Metabolic Syndrome and Altered Gut Microbiota in Mice Lacking Toll-Like Receptor 5
Vijay-Kumar, M., Aitken, J. D., Carvalho, F. A., Cullender, T. C., Mwangi, S., Srinivasan, S., Sitaraman, S. V., Knight, R., Ley, R. E., & Gewirtz, A. T. (2010) · Science · doi:10.1126/science.1179721 · Cited by 2,068
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Self-citationNF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma
Luedde, T., & Schwabe, R. F. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.213 · Cited by 1,345
Self-citationRifaximin Treatment in Hepatic Encephalopathy
Bass, N. M., Mullen, K. D., Sanyal, A., Poordad, F., Neff, G., Leevy, C. B., Sigal, S., Sheikh, M. Y., Beavers, K., Frederick, T., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907893 · Cited by 1,300
Gene expression in fixed tissues and outcome in hepatocellular carcinoma
Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., Chiang, D. Y., Camargo, A., Gupta, S., Moore, J., Wrobel, M. J., Lerner, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804525 · Cited by 1,286
Maeda, S., Kamata, H., Luo, J., Leffert, H. L., & Karin, M. (2005) · Cell · doi:10.1016/j.cell.2005.04.014 · Cited by 1,160
Bacterial translocation (BT) in cirrhosis†
Wiest, R., & Garcia‐Tsao, G. (2005) · Hepatology · doi:10.1002/hep.20632 · Cited by 677
Toll-Like Receptor-4 Promotes the Development of Colitis-Associated Colorectal Tumors
Fukata, M., Chen, A., Vamadevan, A. S., Cohen, J., Breglio, K. J., Krishnareddy, S., Hsu, D. S., Xu, R., Harpaz, N., Dannenberg, A. J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.09.008 · Cited by 623
Deletion of NEMO/IKKγ in Liver Parenchymal Cells Causes Steatohepatitis and Hepatocellular Carcinoma
Luedde, T., Beraza, N., Kotsikoris, V., Loo, G., Nenci, A., Vos, R. D., Roskams, T., Trautwein, C., & Pasparakis, M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.016 · Cited by 603
Regulation of Spontaneous Intestinal Tumorigenesis Through the Adaptor Protein MyD88
Rakoff-Nahoum, S., & Medzhitov, R. M. (2007) · Science · doi:10.1126/science.1140488 · Cited by 594
Focus on hepatocellular carcinoma
Bruix, J., Boix, L., Sala, M., & Llovet, J. M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00058-3 · Cited by 569
Samuel, M. S., Lopez, J. I., McGhee, E. J., Croft, D. R., Strachan, D., Timpson, P., Munro, J., Schröder, E., Zhou, J., Brunton, V. G., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.008 · Cited by 564
Bacterial Infections, Sepsis, and Multiorgan Failure in Cirrhosis
Tandon, P., & García–Tsao, G. (2008) · Seminars in Liver Disease · doi:10.1055/s-2008-1040319 · Cited by 549
Fukui, H., Brauner, B., Bode, J. C., & Bode, C. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90933-3 · Cited by 461
CCR1 and CCR5 promote hepatic fibrosis in mice
Seki, E., De Minicis, S., Gwak, G.-Y., Kluwe, J., Inokuchi, S., Bursill, C. A., Llovet, J. M., Brenner, D. A., & Schwabe, R. F. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37444 · Cited by 431
Self-citationBacterial translocation of enteric organisms in patients with cirrhosis
Cirera, I., Bauer, T., Navasa, M., Vilà, J., Grande, L., Taurá, P., Fuster, J., García‐Valdecasas, J. C., Lacy, A. M., Suárez, M. J., et al. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00013-1 · Cited by 429
He, G., Yu, G.-Y., Temkin, V., Ogata, H., Kuntzen, C., Sakurai, T., Sieghart, W., Peck-Radosavljevic, M., Leffert, H. L., & Karin, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.048 · Cited by 427
A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma
Haybaeck, J., Zeller, N., Wolf, M. J., Weber, A., Wagner, U., Kurrer, M. O., Bremer, J., Iezzi, G., Graf, R., Clavien, P., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.08.021 · Cited by 381
Lin, R.-S., Lee, F.-Y., Lee, S.-D., Tsai, Y.-T., Lin, H. C., Rei-Hwa, L., Wan-Ching, H., Cheng-Chun, H., Sun-Sang, W., & Kwang-Juei, L. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80424-2 · Cited by 355
Yu, L.-X., Yan, H.-X., Liu, Q., Yang, W., Wu, H.-P., Dong, W., Tang, L., Lin, Y., He, Y.-Q., Zou, S.-S., et al. (2010) · Hepatology · doi:10.1002/hep.23845 · Cited by 349
Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis
Inokuchi, S., Aoyama, T., Miura, K., Österreicher, C. H., Kodama, Y., Miyai, K. N., Akira, S., Brenner, D. A., & Seki, E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909781107 · Cited by 283
Isobe, T., Okuyama, T., Toyoda, H., Komurasaki, T., Uchida, D., Takayama, Y., & Hanada, K. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7495 · Cited by 269
Machida, K., Tsukamoto, H., Mkrtchyan, H., Duan, L., Dynnyk, A., Liu, H. M., Asahina, K., Govindarajan, S., Ray, R., Ou, J.-H. J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807390106 · Cited by 223
TAK1 Suppresses a NEMO-Dependent but NF-κB-Independent Pathway to Liver Cancer
Bettermann, K., Vucur, M., Haybaeck, J., Koppe, C., Janssen, J., Heymann, F., Weber, A., Weiskirchen, R., Liedtke, C., Gaßler, N., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.021 · Cited by 219
Modulation of Hepatic Fibrosis by c-Jun-N-Terminal Kinase Inhibition
Kluwe, J., Pradere, J., Gwak, G., Mencin, A., De Minicis, S., Österreicher, C. H., Colmenero, J., Bataller, R., & Schwabe, R. F. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.015 · Cited by 217
Self-citationDolganiuc, A., Norkina, O., Kodys, K., Catalano, D. E., Bakis, G., Marshall, C. P., Mandrekar, P., & Szabó, G. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.003 · Cited by 202
ERK activation drives intestinal tumorigenesis in Apcmin/+ mice
Lee, S. H., Hu, L., González-Navajas, J. M., Seo, G. S., Shen, C., Brick, J., Herdman, S., Varki, N. M., Corr, M., Lee, J., et al. (2010) · Nature Medicine · doi:10.1038/nm.2143 · Cited by 188
Hatano, E., Bennett, B. L., Manning, A. M., Qian, T., Lemasters, J. J., & Brenner, D. A. (2001) · Gastroenterology · doi:10.1053/gast.2001.23239 · Cited by 157
Sakata, H., Takayama, H., Sharp, R., Rubin, J. S., Merlino, G. T., & LaRochelle, W. J. (1996) · PubMed · Cited by 153
Brandl, K., Sun, L., Neppl, C., Siggs, O. M., Gall, S. M. L., Tomisato, W., Li, X., Du, X., Männel, D. N., Blobel, C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014669107 · Cited by 145
Santoni‐Rugiu, E., Preisegger, K., Kiss, A., Audolfsson, T., Shiota, G., Schmidt, E. V., & Thorgeirsson, S. S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9577 · Cited by 121
THE ROLE OF INTESTINAL BACTERIA IN THE DEVELOPMENT OF DIETARY CIRRHOSIS IN RATS
Rutenburg, A. M., Sonnenblick, E., Koven, I., Aprahamian, H. A., Reiner, L., & Fine, J. (1957) · The Journal of Experimental Medicine · doi:10.1084/jem.106.1.1 · Cited by 108
Takami, T., Kaposi-Novák, P., Uchida, K., Gómez-Quiroz, L. E., Conner, E. A., Factor, V. M., & Thorgeirsson, S. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1905 · Cited by 104
Broitman, S. A., Gottlieb, L. S., & Zamcheck, N. (1964) · The Journal of Experimental Medicine · doi:10.1084/jem.119.4.633 · Cited by 99
Common antigens of mouse oval and biliary epithelial cells. Expression on newly formed hepatocytes
Engelhardt, N. V., Factor, V. M., Yasova, A. K., Poltoranina, V. S., Baranov, V. N., & Lasareva, M. N. (1990) · Differentiation · doi:10.1111/j.1432-0436.1990.tb00453.x · Cited by 90
Hsu, D. S., Fukata, M., Hernandez-Barco, Y. G., Sotolongo, J. P., Goo, T., Maki, J., Hayes, L. A., Ungaro, R. C., Chen, A., Breglio, K. J., et al. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.100 · Cited by 84
Differential regulation of rodent hepatocyte and oval cell proliferation by interferon γ†
Brooling, J. T., Campbell, J. S., Mitchell, C., Yeoh, G. C., & Fausto, N. (2005) · Hepatology · doi:10.1002/hep.20645 · Cited by 77
Nolan, J. P., & Leibowitz, A. I. (1978) · Gastroenterology · doi:10.1016/s0016-5085(19)31709-3 · Cited by 35
遠藤, 昌. (2000) · 外科と代謝・栄養 · Cited by 32
Stability of extemporaneously prepared rifaximin oral suspensions
Cober, M. P., Johnson, C. E., Lee, J. J., & Currie, K. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090206 · Cited by 7
Flagged first, then by citations
1 of the 50 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Toyoda, 1995, Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes, J. Biol. Chem., 270, 7495
Cited by
Sorted by citations
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Interaction between microbiota and immunity in health and disease
Zheng, D., Liwinski, T., & Elinav, E. (2020) · Cell Research · doi:10.1038/s41422-020-0332-7 · Cited by 3,947
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., Iwakura, Y., Oshima, K., Morita, H., Hattori, M., et al. (2013) · Nature · doi:10.1038/nature12347 · Cited by 2,219
Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., & Flavell, R. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3611 · Cited by 2,000
Metadata
- Authors
- Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., Lefkowitch, J. H., Bower, M., Friedman, R., Sartor, R. B., Rabadan, R., & Schwabe, R. F.
- Affiliations
- Columbia University (US)
- Samsung Medical Center (KR)
- Hospital Clínic de Barcelona (ES)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Schwabe, Robert F.
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 21
- Issue
- 4
- Pages
- 504-516
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC3332000
- OpenAlex
- W2085153086
- Cited by
- 1,346
- References
- 50
- Citations by year
- 2026: 63 · 2025: 103 · 2024: 106 · 2023: 111 · 2022: 149 · 2021: 133 · 2020: 129 · 2019: 104 · 2018: 93 · 2017: 94 · 2016: 79 · 2015: 64 · 2014: 48 · 2013: 51 · 2012: 16
- FWCI
- 36.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 472 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by)
- UNC Libraries
- Funders
- National Institutes of Health (1F31 DK091980-01, P40RR018603, R01AA020211, R01DK076920, U54CA163111)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- hepatocellular carcinoma, gut microbiota, TLR4, gut-liver axis, chronic liver injury, hepatocarcinogenesis, bacterial translocation, epiregulin, apoptosis, HCC prevention, liver fibrosis, liver inflammation
- MeSH terms
- Animals, Epidermal Growth Factor, Humans, Intestines, Liver Diseases, Liver Neoplasms, Experimental, Mice, Inbred C57BL, Tumor Cells, Cultured, Apoptosis, Bacterial Translocation, Cell Proliferation, Toll-Like Receptor 4, Mice, Epiregulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
